Upstream Bio Q3 2026 earnings

UPB · 2026-11-10 07:05 BMO ET · 8-K on SEC · 10-Q on SEC

Operating expenses increased year-over-year, and net loss widened, despite a reduction in cash and cash equivalents.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$0.395M-42.1%-48.9%Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $43.8M (+13.7% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge not stated in the 8-K

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$47.4M$79.4M$101.6M-40.5% QoQ, -53.4% YoY
Short-term investments$159.9M$181.9M$239.9M-12.1% QoQ, -33.4% YoY

Guidance

not stated in the 8-K

What drove it

  • Revenue story Collaboration revenue decreased 42.1% year-over-year and 48.9% quarter-over-quarter.
  • EPS story Net loss widened year-over-year due to higher operating expenses and lower interest income.
  • One-off check not stated in the 8-K

The good

  • Cash and cash equivalents of $47.4M as of September 30, 2026, with cash, cash equivalents and short-term investments totaling $207.4M, expected to fund planned operations through 2027.

The bad

  • Net loss widened to $41.2 million from $33.7 million in the prior year.
  • Operating expenses increased year-over-year, driven by personnel-related expenses and clinical costs.

The ugly

  • none

Open questions

  • The filing does not disclose the specific prior-year tax rate or provide a reconciliation of GAAP to non-GAAP results.
Full release

Upstream Bio (UPB) earnings release, November 10, 2026

Upstream Bio, Inc. (UPB) · Form 8-K, Item 2.02 · Filed · SEC filing

Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress – Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – – Prioritizing Phase 3 development strategy designed to deliver best-in-class efficacy and convenient quarterly dosing – WALTHAM, Mass. – November 10, 2026

-

Upstream Bio, Inc.

(Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today reported financial results and business updates for the third quarter ended September 30, 2026. The Company highlighted its continued progress in developing verekitug to deliver potential best-in-class efficacy with quarterly dosing across three target indications: severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). Verekitug is the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (

TSLP) receptor.

“Our team is focused on the timely execution of startup activities for verekitug’s Phase 3 trials in severe asthma and CRSwNP. Preparations for the planned initiation of these trials in the first quarter of 2027 are well underway, with key clinical, regulatory, and manufacturing milestones now having been achieved,” said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio. “With the substantial and consistent clinical evidence generated across our programs to date, we believe that verekitug has the potential to make a meaningful difference for patients living with these diseases. As we look ahead, we remain focused on advancing verekitug in diseases with significant remaining unmet medical need, where we believe its compelling efficacy profile and convenient quarterly at-home dosing have the opportunity to meaningfully redefine treatment expectations and establish a new standard of care.”

Additional Business Highlights

• Trials in COPD and Severe Asthma Long-Term Extension (LTE) Ongoing o

The Phase 2 VENTURE trial in COPD (

NCT06981078) remains ongoing with approximately 480 participants enrolled. VENTURE is a global, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to assess the efficacy and safety of verekitug in adults with moderate-to-severe COPD across extended dosing-interval arms of 12 and 24 weeks, with a primary endpoint of annualized COPD exacerbation rates. Enrollment completion was announced in August 2026 and data from the study are expected in the second half of 2027. The Company believes that this trial will provide important insights into the potential clinical impact of verekitug in COPD. o

The Phase 2 VALOUR (

NCT06966479) LTE study in severe asthma also remains ongoing, with more than 90% retention of eligible participants from the Phase 2 VALIANT study. VALOUR is a dose-blinded, active treatment extension study for eligible participants with severe asthma who completed the Phase 2 VALIANT study to assess the long-term efficacy and safety outcomes of verekitug. Data from the study are expected in the second half of 2027.

Third Quarter 2026 Financial Results

As of September 30, 2026, Upstream Bio had cash, cash equivalents and short-term investments of $207.4 million, which is expected to fund planned operations through 2027.

Research and development expenses were $36.6 million for the quarter ended September 30, 2026, compared to $33.0 million for the same period in 2025. The increase of $3.6 million was primarily driven by an increase in personnel-related expenses, including share-based compensation, and an increase in clinical costs related to the Company’s verekitug programs.

General and administrative expenses were $7.2 million for the quarter ended September 30, 2026, compared to $5.5 million for the same period in 2025. The increase of $1.7 million was primarily driven by an increase in personnel-related expenses, including share-based compensation, and an increase in professional fees.

Net loss was $41.2 million for the quarter ended September 30, 2026, compared to a net loss of $33.7 million for the same period in 2025.

Upcoming Events

Upstream Bio expects to participate in the following upcoming investor conferences:

• Truist Securities 2026 Biopharma Symposium, November 12, New York, NY

• 9 th

Annual Evercore Healthcare Conference, November 30–December 2, Coral Gables, FL

• 38 th

Annual Piper Sandler Healthcare Conference, December 1–3, New York, NY

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company developing treatments for severe inflammatory respiratory diseases. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple inflammatory pathways. With more than 500 participants treated with verekitug across its clinical development programs and positive Phase 2 results in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, verekitug has a substantial body of clinical evidence supporting its advancement into Phase 3 development in both diseases. Verekitug is also being evaluated in an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD). Upstream Bio is focused on leveraging verekitug’s differentiated mechanism, potency, and potential for extended dosing to develop a treatment which may deliver best-in-class efficacy and quarterly dosing for patients underserved by today’s standard of care.

To learn more, please visit www.upstreambio.com.... (truncated)website in addition to following press releases, filings with the Securities and Exchange Commission (SEC), public conference calls, presentations and webcasts.

Financial statements

Income Statement

Three Months Ended September 30, — (UNAUDITED) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Collaboration revenue3956832,2022,186
Operating expenses:
Research and development36,60932,975109,26396,637
General and administrative7,1655,54222,30119,743
Total operating expenses43,77438,517131,564116,380
Loss from operations-43,379-37,834-129,362-114,194
Other income (expense):
Interest income2,2304,1057,94313,279
Other expense, net-43-19-66-69
Total other income, net2,1874,0867,87713,210
Net loss-41,192-33,748-121,485-100,984

Balance Sheet

September 30, — (UNAUDITED) (in thousands)

September 30, – 2026December 31, – 2025
Current assets:
Cash and cash equivalents47,416101,578
Short-term investments159,949239,931
Accounts receivable395668
Prepaid expenses and other current assets36,8739,620
Total current assets244,633351,797
Property and equipment, net411559
Operating lease right-of-use assets7541,222
Restricted cash194194
Total assets245,992353,772
Current liabilities:
Accounts payable2,3852,726
Accrued expenses and other current liabilities8,84310,006
Operating lease liabilities, current portion732720
Total current liabilities11,96013,452
Operating lease liabilities, net of current portion57549
Total liabilities12,01714,001
Stockholders’ equity:
Common stock5454
Additional paid-in capital689,956673,410
Accumulated other comprehensive income (loss)-327530
Accumulated deficit-455,708-334,223
Total stockholders’ equity233,975339,771
Total liabilities and stockholders’ equity245,992353,772

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (Unaudited) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-121,485-100,984
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense148131
Stock-based compensation expense13,3467,826
Net amortization of premiums and accretion of discounts on short-term investments-1,216-2,874
Non-cash lease expense468415
Changes in operating assets and liabilities:
Accounts receivable273-70
Prepaid expenses and other assets-27,253-7,811
Accounts payable-341-55
Accrued expenses and other current liabilities-1,1631,193
Operating lease liabilities-480-415
Net cash used in operating activities-137,703-102,644
Cash flows from investing activities:
Purchases of short-term investments-81,132-347,596
Maturities of short-term investments161,473195,285
Purchases of equipment-111
Net cash provided by (used in) investing activities80,341-152,422
Cash flows from financing activities:
Proceeds from issuance of common stock in connection with at-the-market offering, net of commissions2,083
Proceeds from issuance of common stock under stock plans1,1171,372
Payments of initial public offering costs-34
Net cash provided by financing activities3,2001,338
Net decrease in cash, cash equivalents and restricted cash-54,162-253,728
Cash, cash equivalents and restricted cash at beginning of period101,772326,086
Cash, cash equivalents and restricted cash at end of period47,61072,358
Cash, cash equivalents and restricted cash at end of period:
Cash and cash equivalents47,41672,164

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “predict,” “project,” “seeks,” “should,” “target,” “will” and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: the clinical development of verekitug for the treatment of severe asthma, CRSwNP and COPD, including the Company’s expectations and preparations for the initiation of Phase 3 clinical trials in severe asthma and CRSwNP in the first quarter of 2027 and the timing, progress and results of ongoing and planned clinical trials; expectations to report data from the Phase 2 VENTURE trial in COPD and the Phase 2 VALOUR long-term extension study in severe asthma in the second half of 2027; expectations regarding the potential of verekitug to deliver best-in-class efficacy and its differentiation, safety and tolerability; certain activities and next steps to support the Company’s maturation into a late clinical-stage company; expectations regarding regulatory interactions with the U.S. Food and Drug Administration; verekitug’s potential to address unmet medical needs, improve outcomes for patients, and establish a new standard of care with quarterly at-home administration; Upstream Bio’s expected operating expenses and capital expenditure requirements, including its cash runway through 2027; and participation at upcoming investor conferences. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream Bio’s ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the initiation, timing, progress and results of clinical trials; Upstream Bio’s ability to fund its development activities and achieve development goals; Upstream Bio’s dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream Bio’s ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream Bio’s financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream Bio’s competitors and industry; and other risks and uncertainties described in greater detail under the caption “Risk Factors” in Upstream Bio’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Upstream Bio’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Investor and Media Contact:

Meggan Buckwell

Director, Corporate Communications and Investor Relations ir@upstreambio.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.